TMCI (Treace Medical Concepts, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TMCI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | John T. Treace | Chief Executive Officer | Buy | — | — |
| 2026-08-12 | Sean F. Scanlan | Chief Innovation Officer | F | — | — |
| 2026-08-12 | Mark Hair | Chief Financial Officer | F | — | — |
| 2026-08-12 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | F | — | — |
| 2026-06-12 | John T. Treace | Chief Executive Officer | Buy | — | — |
| 2026-06-11 | John T. Treace | Chief Executive Officer | Buy | — | — |
| 2026-06-01 | John T. Treace | Chief Executive Officer | Buy | — | — |
| 2026-05-28 | John T. Treace | Chief Executive Officer | Buy | — | — |
| 2026-05-19 | Deepti Jain | Director | A | — | — |
| 2026-05-19 | JOHN K BAKEWELL | Director | A | — | — |
| 2026-05-19 | Jane E Kiernan | Director | A | — | — |
| 2026-05-19 | Betsy Hanna | Director | A | — | — |
| 2026-05-19 | LAWRENCE W HAMILTON | Director | A | — | — |
| 2026-05-19 | Lance A Berry | Director | A | — | — |
| 2026-05-14 | John T. Treace | Chief Executive Officer | Buy | — | — |
| 2026-04-20 | Mark Hair | Chief Financial Officer | F | — | — |
| 2026-04-03 | Mark Hair | Chief Financial Officer | A | — | — |
| 2026-03-11 | Sean F. Scanlan | Chief Innovation Officer | F | — | — |
| 2026-03-11 | John T. Treace | Chief Executive Officer | F | — | — |
| 2026-03-11 | Mark Hair | Chief Financial Officer | F | — | — |
| 2026-03-11 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | F | — | — |
| 2026-02-11 | Sean F. Scanlan | Chief Innovation Officer | M | — | — |
| 2026-01-23 | Mark Hair | Chief Financial Officer | MIXED | — | — |
| 2026-01-23 | John T. Treace | Chief Executive Officer | MIXED | — | — |
| 2026-01-23 | Gaetano Guglielmino | Chief Commercial Officer | A | — | — |
| 2026-01-23 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | MIXED | — | — |
| 2026-01-23 | Sean F. Scanlan | Chief Innovation Officer | MIXED | — | — |
| 2026-01-13 | Mark Hair | Chief Financial Officer | F | — | — |
| 2026-01-13 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | F | — | — |
| 2026-01-13 | John T. Treace | Chief Executive Officer | F | — | — |
| 2025-12-03 | Guy Guglielmino | Chief Commercial Officer | F | — | — |
| 2025-10-28 | Sean F. Scanlan | Chief Innovation Officer | F | — | — |
| 2025-10-28 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | F | — | — |
| 2025-10-02 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | F | — | — |
| 2025-08-12 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | F | — | — |
| 2025-08-12 | Aaron Berutti | SVP, Sales | F | — | — |
| 2025-08-12 | Sean F. Scanlan | Chief Innovation Officer | F | — | — |
| 2025-08-12 | Mark Hair | Chief Financial Officer | F | — | — |
| 2025-07-22 | Sean F. Scanlan | Chief Innovation Officer | M | — | — |
| 2025-05-21 | Lance A Berry | Director | A | — | — |
| 2025-05-21 | LAWRENCE W HAMILTON | Director | A | — | — |
| 2025-05-21 | Deepti Jain | Director | A | — | — |
| 2025-05-21 | RICHARD W MOTT | Director | A | — | — |
| 2025-05-21 | Betsy Hanna | Director | A | — | — |
| 2025-05-21 | Jane E Kiernan | Director | A | — | — |
| 2025-05-21 | JOHN K BAKEWELL | Director | A | — | — |
| 2025-05-12 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | MIXED | — | — |
| 2025-03-19 | Sean F. Scanlan | Chief Innovation Officer | MIXED | — | — |
| 2025-03-11 | Scot Michael Elder | Chief Legl & Comp Off, CorpSec | F | — | — |
| 2025-03-11 | Mark Hair | Chief Financial Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 9,243,446 | — |
| — | Director | 1,860,478 | — |
| — | Director | 1,779,624 | — |
| — | Director | 1,230,611 | — |
| — | Director | 1,151,364 | — |
| — | Director | 1,042,318 | — |
| — | Chief Financial Officer | 916,100 | — |
| — | Chief Legl & Comp Off, CorpSec | 778,683 | — |
| — | Chief Innovation Officer | 679,863 | — |
| — | SVP, Research & Development | 505,331 | — |
| — | Chief Commercial Officer | 490,901 | — |
| — | Director | 454,056 | — |
| — | Chief Legal Officer | 276,208 | — |
| — | SVP, Sales | 205,092 | — |
| — | Director | 100,243 | — |
| — | Director | 93,949 | — |
| — | Director | 75,243 | — |
| — | Director | 74,593 | — |
| — | Director | 74,056 | — |
| — | Chief Human Resources Officer | 37,164 | — |
| — | SVP, Operations | 3,350 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TMCI quote page; the site-wide leaderboard is on the insider transactions hub.